结缔组织病合并血小板减少的药物治疗进展  

Progress in Pharmacological Treatment of Connective Tissue Disease Complicated with Thrombocytopenia

作　　者：考赛尔·买买提艾力 罗莉[1] Kawsar Mamatei;Luo Li(The First Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang 830054)

机构地区：[1]新疆医科大学第一附属医院,新疆乌鲁木齐830054

出　　处：《科技与健康》2025年第4期61-64,共4页Technology and Health

摘　　要：结缔组织病(connective tissue disease,CTD)是一组主要侵犯全身结缔组织的系统性自身免疫性疾病,易合并系统性红斑狼疮(systemic lupus erythematosus,SLE)、原发性干燥综合征(primary sjögren syndrome,PSS)等疾病。CTD合并免疫性血小板减少症(immune thrombocytopenia,ITP)患者的出血风险较高,病情严重者可能出现内脏出血,病死率高,是影响CTD患者预后的重要因素。近年来,有关CTD-ITP的发病机制及治疗方法的研究取得了较大突破,新型治疗药物的使用让更多患者获益。目前,复发难治性CTD-ITP患者的治疗选择有限。对CTD-ITP患者的药物治疗进展进行综述,旨在为CTD-ITP患者药物治疗策略的制订和进一步的临床研究提供参考。Connective tissue disease(CTD)is a group of systemic autoimmune diseases mainly affecting the connective tissues throughout the body,and it is prone to be complicated with diseases such as systemic lupus erythematosus(SLE)and primary sjögren syndrome(PSS).Patients with CTD complicated with immune thrombocytopenia(ITP)have a relatively high risk of bleeding.In severe cases,visceral bleeding may occur,and the fatality rate is high,which is an important factor affecting the prognosis of CTD patients.In recent years,significant breakthroughs have been made in the research on the pathogenesis and treatment methods of CTD-ITP,and the use of new therapeutic drugs has benefited more patients.Currently,the treatment options for patients with relapsed and refractory CTD-ITP are limited.This study reviews the progress in the pharmacological treatment of CTD-ITP patients,aiming to provide a reference for the formulation of pharmacological treatment strategies for CTD-ITP patients and for further clinical research.

关 键 词：结缔组织疾病 免疫性血小板减少症 系统性红斑狼疮 

分 类 号：R558[医药卫生—血液循环系统疾病]